Pacer Advisors Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 33.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,493,442 shares of the biopharmaceutical company’s stock after purchasing an additional 867,597 shares during the period. Gilead Sciences accounts for about 1.2% of Pacer Advisors Inc.’s investment portfolio, making the stock its 6th biggest holding. Pacer Advisors Inc. owned approximately 0.28% of Gilead Sciences worth $289,851,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of the business. Geode Capital Management LLC lifted its position in Gilead Sciences by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 23,848,477 shares of the biopharmaceutical company’s stock worth $2,044,282,000 after acquiring an additional 244,886 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares in the last quarter. Morgan Stanley grew its position in Gilead Sciences by 11.5% in the fourth quarter. Morgan Stanley now owns 17,196,950 shares of the biopharmaceutical company’s stock valued at $1,476,358,000 after acquiring an additional 1,780,489 shares during the period. Renaissance Technologies LLC raised its stake in Gilead Sciences by 70.6% during the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after acquiring an additional 6,410,047 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Gilead Sciences by 14.8% during the third quarter. Bank of New York Mellon Corp now owns 15,421,436 shares of the biopharmaceutical company’s stock valued at $951,350,000 after acquiring an additional 1,987,058 shares during the period. Institutional investors and hedge funds own 81.59% of the company’s stock.
Gilead Sciences Price Performance
GILD traded up $0.58 during trading on Friday, hitting $80.52. 2,440,435 shares of the stock traded hands, compared to its average volume of 5,769,984. Gilead Sciences, Inc. has a twelve month low of $59.27 and a twelve month high of $89.74. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.28 and a quick ratio of 1.13. The business has a 50 day moving average price of $77.49 and a 200 day moving average price of $80.93. The company has a market cap of $100.44 billion, a price-to-earnings ratio of 18.05, a PEG ratio of 0.90 and a beta of 0.38.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.37 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.26). Gilead Sciences had a net margin of 20.65% and a return on equity of 39.35%. The company had revenue of $6.35 billion during the quarter, compared to analyst estimates of $6.33 billion. During the same quarter in the prior year, the business earned $2.12 EPS. The business’s quarterly revenue was down 3.6% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post 6.71 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Thursday, June 29th. Shareholders of record on Thursday, June 15th were given a $0.75 dividend. The ex-dividend date was Wednesday, June 14th. This represents a $3.00 annualized dividend and a yield of 3.73%. Gilead Sciences’s dividend payout ratio is presently 67.72%.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Merdad Parsey sold 1,485 shares of the company’s stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $76.90, for a total value of $114,196.50. Following the completion of the transaction, the insider now directly owns 29,402 shares in the company, valued at approximately $2,261,013.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.21% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on GILD. Cantor Fitzgerald lowered their target price on shares of Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday. StockNews.com began coverage on Gilead Sciences in a report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Morgan Stanley boosted their target price on Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 12th. BMO Capital Markets reduced their target price on Gilead Sciences from $100.00 to $95.00 in a report on Tuesday. Finally, Barclays cut their price target on Gilead Sciences from $84.00 to $81.00 in a report on Tuesday, July 11th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $91.10.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Gilead Sciences wasn’t on the list.
While Gilead Sciences currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.
